B+
Bull case
0%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-04-20 · RankAlpha Sentiment Codex
DFTX
Definium TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The positive case is that DFTX has one of the cleaner late-stage psychiatric development setups in small-cap biotech: a fully enrolled first Phase 3 MDD study, a second Phase 3 MDD study moving forward, additional GAD framing around DT120, and cash, cash equivalents, and investments of about $411.6 million at December 31, 2025 that management says should fund operations into 2028 [#10-K-2026-02-26]. If April messaging de-risks the path to late-Q2 data and the Emerge readout is supportive, the shares can move materially toward the existing median target neighborhood.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
Despite runway into 2028 per the 10-K, prolonged development setbacks could eventually force a lower-quality financing outcome.
Momentum
61
Value
41
Sentiment
13
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.00 · Bull $34.00 · Bear $14.00Analysis 2026-04-20; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $67.47
Why
Momentum61 · Δ7d -23.2
Value41 · Δ7d 0.0
Sentiment13 · Δ7d +3.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • Despite runway into 2028 per the 10-K, prolonged development setbacks could eventually force a lower-quality financing outcome.
- • Execution or timing slippage in Ascend or other DT120 studies could weaken confidence in the broader program.
- • The negative case is that the stock is still mainly a single-platform clinical bet with low coverage and a negative structured prior across 5d, 20d, 60d, and 120d horizons.
Catalyst clock
2026-04-22
April 22, 2026 investor and analyst day may sharpen readout expectations
Lead driver: Value · See fundamentals
Momentum
61
9% active weight
Current posture
7d trendSoftening
Δ7d
-23.2
Δ21d
-37.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
13
62% active weight
Current posture
7d trendImproving
Δ7d
+3.4
Δ21d
+13.1
Why this grade
Composite grade F. Momentum 60.7 / Value 41.2 / Sentiment 13.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-20. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-04-20 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-04-20 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$6.08B
Beta
2.62
Shares Out
134.37M
P/E (TTM) · Derived
-22.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-27.65
Rev YoY
-
EPS YoY
+186.8%
Gross Margin
-
Op Margin
-
Net Debt
-$371.01M
Current Ratio
6.95
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data